摘要
目的评价阿仑膦酸钠加雌孕激素、阿仑膦酸钠治疗绝经后骨质疏松症、骨量减少临床疗效及消化道副作用。方法92例绝经后骨质疏松症、骨量减少女性作为期1年随机双盲、安慰剂平行对照研究。用药1年比较治疗前后SOS、T值和消化道副作用。治疗前、治疗后1年应用超声定量骨密度仪进行胫骨SOS、T值测定,记录病人腹痛、恶心、消化不良情况。结果用药组A组、B组治疗1年胫骨SOS分别平均增加9.87%、5.69%,T值分别平均上升80.67%、59.56%,分别与C组比较差异有显著性(P<0.01)。A组、B组治疗半年,分别出现腹痛3.2%、6.7%,发生恶心3.2%、3.3%,明显消化不良3.2%、3.3%,2组分别与C组比较差异无显著性(P>0.05);A组、B组治疗1年分别出现腹痛3.2%、6.7%,发生恶心3.2%、3.3%,明显消化不良6.5%、6.7%,分别与C组比较差异无显著性(P>0.05)。结论阿仑膦酸钠加雌孕激素、单用阿仑膦酸钠治疗绝经后骨质疏松症、骨量减少有效且消化道副作用较轻。
Objective To evaluate effect and Digestive tract side effect of alendronate sodium plus HRT or alendronate on bone mineral density in postmenopausal women with primary osteoporosis. Methods Ninety-two women with postmenopausal duration more than one year were divided into 3 groups. Group A： 31 cases,mean age 52.5± 2.4（46-56）years,one year therapy： Group B ： 30 cases,mean age 53.0±2.6 （47-57）years,one year therapy ; Group C：31 cases,,52.7±2.4 （46-58） years, one year therapy. patients in Group A received alendronate （10mg/d） and HRT（Conjugated estrogen 0.625mg/d× 21d＋Mebroxyprogesterne acetate 6mg/ d× 10d）from one year. patients in Group B received alendronate （10mg/d） from one year. Compared with patients in Group C received elementary calcium（600mg/d） from one year.To observe BMD and Digestive tract side effect etc.Results Group A ： in the one year SOS increased markedly compared with Group C（P〈0.01）;Group B：in the one year SOS increased markedly compared with Group C （P〈0.01）.Digestive tract side effect increased nonmarkly in the 6th month and one year compared with Group C（P〉0.05）.Conclusions long time alendronate and HRT,alendronate is an efficient and safe procedure in treating the primary osteoporosis of postmenopausal.
出处
《中外医疗》
2009年第22期5-7,共3页
China & Foreign Medical Treatment
